Avricore Health Inc V.AVCR

Alternate Symbol(s): AVCRF

Healthcare Diagnostics & Research

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.

TSXV:AVCR - Post by User

Avricore Health Inc

Bullboard Posts

Post by NycePriceon Apr 01, 2015 3:29pm

147 Views

Post# 23588461

Health Care Sector on VSX

MOM looking for a POP

Anything Under a Dime "Should be Cleaned Up and Second Now"

BECAUSE this is Really OVERSOLD!

Miraculins’ focus is non-invasive medical diagnostic and risk assessment tests.

CHINA Deal that could eventually lead to as much as $90 million in revenue for Miraculins, Catalyn Medical Technologies Limited, a privately-owned and Hong Kong based medical device import company, has agreed to be the exclusive distributor in China of Miraculins’ Scout DS diabetes screening devices.

One of our major goals for 2015 will be to drive towards the goal of CFDA regulatory approval for the Scout DS® in China. This approval will trigger a $15M USD order of Scout DS® units and will be the first major revenue transaction for Miraculins.

image: https://stockcharts.com/c-sc/sc?s=MOM.V&p=D&yr=0&mn=5&dy=0&i=p50355111872&r=1427827575265

One of our major goals for 2015 will be to drive towards the goal of CFDA regulatory approval for the Scout DS® in China. This approval will trigger a $15M USD order of Scout DS® units and will be the first major revenue transaction for Miraculins. As part of this process, Miraculins is working hard to ensure that its manufacturing processes will be ready to effectively supply the market demand for the product both in China as well as other world markets.In addition, another major milestone for the Company will be achieving clarity from the U.S. FDA on the best path for regulatory approval for the Scout DS® and to begin the corresponding clinical trial. The Company is also planning to begin pilot programs for the Scout DS® both in the retail and food pharmacy market segment as well as the workplace screening segment in Canada

Read more at https://www.stockhouse.com/companies/bullboard/v.mom/miraculins-inc#ERDeoUREKiSwJR81.99

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale